Risultati di ricerca
2 giorni fa · Delayed diagnosis and treatment resistance make pancreatic ductal adenocarcinoma (PDAC) mortality rates high. Identifying molecular subtypes can improve treatment, but current methods are costly and time-consuming. In this study, deep learning models were utilized to identify histological features that classify PDAC molecular subtypes based on routine hematoxylin-eosin (H&E)-stained ...
4 giorni fa · PDAC arises from precancerous lesions in the pancreas. One of these lesion types, pancreatic intraepithelial neoplasias (PanINs), can appear in the pancreas years before they progress to invasive cancer. Because PanINs are so small, they cannot be detected by conventional clinical imaging tests.
5 giorni fa · Treatment of transplanted and autochthonous PDAC mouse models with these regimens led to enhanced uptake of NPs by multiple cell types in the PDAC TME, induction of type I interferon and other proinflammatory signaling pathways, increased antigen presentation by tumor cells and antigen-presenting cells, and subsequent activation of both innate and adaptive immune responses.
5 giorni fa · Background We have previously demonstrated the significant reliance of pancreatic Cancer Stem Cells (PaCSCs) on mitochondrial oxidative phosphorylation (OXPHOS), which enables versatile substrate utilization, including fatty acids (FAs). Notably, dysregulated lipid scavenging and aberrant FA metabolism are implicated in PDAC progression. Methods & results Our bioinformatics analyses revealed ...
3 giorni fa · Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related death, with one in 64 individuals expected to die from this disease 1.The poor prognosis ...
5 giorni fa · Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer.With a dismal 13% five-year survival rate, it is the third leading cause of cancer deaths.
McIntyre et al. demonstrate in an analysis of 1,360 patients the key features of early-stage pancreatic ductal adenocarcinoma (PDAC), including an enrichment of KRASG12R disease that extensively associates with improved outcomes.
